Table II.

Study outcomes stratified by transfusion activity.

	Periods of transfusions*
	No transfusions (n = 3515)	Transfusions (n = 1196)
Number of unique patients	3515	1105
Mean (SD) Charlson comorbidity index score†	2.04 (2.19)	2.72 (2.42)
Mean duration, days (SD)	465 (352)	356 (323)
Mean (SD) number of whole/RBC transfusions	0 (0)	0.53 (0.64)
Number (%) of patients with platelet  transfusions	77 (2)	349 (29)
Number (%) of periods with ESA‡	215 (6)	156 (13)
Number (%) of periods with G-CSF/GM-CSF‡	255 (7)	218 (18)
Events	n (%)	n (%)
Infection	1715 (49)	829 (69)
Significant bleeding	838 (24)	500 (42)
Inpatient hospitalization	1234 (35)	919 (77)
ER visit	1538 (44)	840 (70)
	Incidence per person-year (95% CI)
Infection	0.61 (0.59–0.64)	1.57 (1.47–1.68)
Significant bleeding	0.23 (0.21–0.24)	0.64 (0.59–0.70)
Inpatient hospitalization	0.37 (0.35–0.39)	1.91 (1.79–2.04)
ER visit	0.51 (0.49–0.54)	1.59 (1.49–1.70)

SD, standard deviation; RBC, red blood cell; ESA, erythropoietic-stimulating agent; G-CSF/GM-CSF, granulocyte-colony stimulating factor/granulocyte macrophage-colony stimulating factor; ER, emergency room; CI, confidence interval.

^*Periods of therapy may or may not have included ESAs.

^†Reflects baseline Charlson comorbidity index score.

^‡p<0.05.